1. Marino M, Rizzotti D, Leonardi S. Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX). Current Cardiology Reports. 2014;16(6):493.
2. Ferri N, Corsini A, Bellosta S. Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties. Drugs. 2013;73(15):1681-709.
3. Keating GM. Cangrelor: A Review in Percutaneous Coronary Intervention. Drugs. 2015;75(12):1425-34.
4. Baker DE, Ingram KT. Cangrelor. Hospital Pharmacy. 2015;50(10):922-9.
5. Waite LH, Phan YL, Spinler SA. Cangrelor: A Novel Intravenous Antiplatelet Agent with a Questionable Future. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2014;34(10):1061-76.
6. Cattaneo M. 51 - P2Y12 Antagonists. In: Michelson AD, editor. Platelets (Fourth Edition): Academic Press; 2019. p. 937-56.
7. Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, et al. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2017;69(2):176-85.
8. Gencer B, Brotons C, Mueller C, Mukherjee D, Chew DP, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal.
2016;37(3):267-315.
9. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002;13(7):407-13.
)
View on SCiNiTO